Phase I Study Of Prolonged Low Dose Decitabine (5-Aza-Deoxycitidine, NSC # 127716) In Patients With Biopsiable Advanced Cancers Refractory To Standard Therapy
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2013
At a glance
- Drugs Decitabine (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 04 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Oct 2009 Planned number of patients changed from 24 to 36 as reported by ClinicalTrials.gov.
- 17 Apr 2008 Status changed from recruiting to completed according to clinicaltrials.gov.